THE LANCET

Supplementary appendix

This appendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors.

Supplement to: Mboi N, Surbakti IM, Trihandini I, et al. On the road to universal health care in Indonesia, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. *Lancet* 2018; published online June 28. http://dx.doi.org/10.1016/S0140-6736(18)30595-6.

Appendix

Contents

| GATHER Table | e2 |
|--------------|---|
| Methods | |
| 1. Data | |
| 2. Morta | lity16 |
| 3. Morbi | dity16 |
| 4. Socio- | demographic Index |
| Supplementa | l figures |
| _ | 1. Attribution of changes in under-5 mortality for Indonesia and comparator countries to in major groups of causes of death, 1990–201618 |
| | 2. Leading 30 Level 3 causes of mortality in Indonesia for 1990, 2006, and 2016, with change in number of mortalities, and all-age and age-standardised mortality rates21 |
| _ | 3. Age-standardised rates of YLLs for males versus females in Indonesia and comparator s, (A) 1990, (B) 201623 |
| _ | 4. Leading 30 Level 3 causes of YLLs in Indonesia for 1990, 2006, and 2016, with percent n number of YLLs, and all-age and age-standardised YLL rates |
| • | 5. Leading 30 Level 3 causes of YLDs in Indonesia for 1990, 2006, and 2016, with percent n number of YLDs, and all-age and age-standardised YLD rates28 |
| • | 6. Leading 30 Level 3 risk factors for YLLs in Indonesia for 1990, 2006, and 2016, with change in number of YLLs, and all-age and age-standardised YLL rates |
| • | 7. Ratio of observed to expected age-standardised YLLs in Indonesia and comparator s, 1990 and 2016, with uncertainty intervals32 |

Appendix Table 1. Guidelines for Accurate and Transparent Health Estimates Reporting (GATHER) checklist of information that should be included in reports of global health estimates, with description of compliance and location of information for "On the road to universal health care in Indonesia, 1990 to 2016: a systematic analysis for the Global Burden of Disease Study 2016."

| inac | onesia, 1990 to 2016: a systematic analysis for t | he Global Burden of Diseas | e Study 2016." |
|------|---|--|---|
| # | GATHER checklist item | Description of Compliance | Reference |
| 01: | and an and for dear | Compliance | |
| 1 | Define the indicators, populations, and time periods for which estimates were made. | Narrative provided in paper and methods | Main text (Methods) and methods appendix |
| | | appendix describing indicators, definitions, and populations | |
| 2 | List the funding sources for the work. | Funding sources listed in paper | Summary (Funding) |
| Data | a Inputs | | |
| For | all data inputs from multiple sources that are sy | nthesized as part of the stu | dy: |
| 3 | Describe how the data were identified and how the data were accessed. | Narrative description of data-seeking methods | GBD 2016 Mortality appendix (pgs 6-9, 21- |
| | now the data were decessed. | provided | 25, 53, 58-60), Cause |
| | | in the GBD 2016 | of death appendix |
| | | publications* and | (pgs 9-13), Years lived |
| | | methods | with disabilities (YLDs) |
| | | appendices** | appendix (pgs 6-17) |
| 4 | Specify the inclusion and exclusion criteria. Identify all ad-hoc exclusions. | Narrative about inclusion and exclusion criteria by data type provided in the GBD 2016 publications* and methods appendices** | GBD Mortality appendix (pgs 6-9, 21-25, 53, 58-60) Cause of death appendix (by cause pgs 39-278), YLDs appendix (by cause pgs 34-716) |
| 5 | Provide information on all included data sources and their main characteristics. For each data source used, report reference information or contact name/institution, population represented, data collection method, year(s) of data collection, sex and age range, diagnostic criteria or measurement method, and sample size, as relevant. | An interactive, online data source tool that provides metadata for data sources by component, geography, cause, risk, or impairment has been developed | Online data citation tools http://ghdx.healthdata .org/ |

| 6 | Identify and describe any categories of input data that have potentially important biases (eg, based on characteristics listed in item 5). | Summary of known biases by cause provided in the GBD 2016 publications* and methods appendices ** | Main Text, Limitations section in GBD Mortality, Cause of death, and YLD papers Cause of death appendix (by cause pgs 39-278), YLDs appendix (by cause pgs 34-716) |
|-----|--|--|---|
| For | data inputs that contribute to the analysis but w | vere not synthesised as par | t of the study: |
| 7 | Describe and give sources for any other data inputs. | Included in online data source tool | Online data citation tools http://ghdx.healthdata .org/ |
| For | all data inputs: | | |
| 8 | Provide all data inputs in a file format from which data can be efficiently extracted (eg, a spreadsheet as opposed to a PDF), including all relevant metadata listed in item 5. For any data inputs that cannot be shared due to ethical or legal reasons, such as third-party ownership, provide a contact name or the name of the institution that retains the right to the data. | Downloads of input data available through online tools, including data visualisation tools and data query tools; input data not available in tools will be made available upon request | Online data visualisation tools, data query tools, and the Global Health Data Exchange www.healthdata.org /results/data- visualizations; http://ghdx.healthda ta.org/gb-results- tool; http://ghdx.healt hdata.org/ |
| Dat | a analysis | | |
| 9 | Provide a conceptual overview of the data analysis method. A diagram may be helpful. | Flow diagrams of the overall methodological processes, as well as cause-specific modelling processes, have been provided in the GBD 2016 publications* and methods appendices** | GBD Mortality appendix figure 1, Cause of death appendix figures 1-3, YLDs appendix figures 1-2 |

| 10 | Provide a detailed description of all steps of the analysis, including mathematical formulae. This description should cover, as relevant, data cleaning, data pre-processing, data adjustments and weighting of data sources, and mathematical or statistical model(s). | Flow diagrams and corresponding methodological write-ups for each cause, as well as the demographics and causes of death databases and modelling processes, have been provided in the GBD 2016 publications* and methods appendices** | GBD Mortality appendix figure 1, Cause of death appendix figures 1-3, YLDs appendix figures 1-2 GBD Cause of death appendix (by cause pgs 39-278), YLDs appendix (by cause pgs 34-716) |
|----|---|---|--|
| 11 | Describe how candidate models were evaluated and how the final model(s) were selected. | Provided in the methodological write-ups in the GBD 2016 publications* and methods appendices ** | GBD Cause of death appendix (by cause pgs 39-278), YLDs appendix (by cause pgs 34-716) |
| 12 | Provide the results of an evaluation of model performance, if done, as well as the results of any relevant sensitivity analysis. | Provided in the methodological write-ups in the GBD 2016 publications* and methods appendices ** | GBD Cause of death appendix (by cause pgs 39-278), YLDs appendix (by cause pgs 34-716) |
| 13 | Describe methods for calculating uncertainty of the estimates. State which sources of uncertainty were, and were not, accounted for in the uncertainty analysis. | Narrative provided in the main paper Further detail available in the GBD 2016 publications* and methods appendices** | Main text (Methods) GBD Cause of death appendix (pgs 9, 33-35), YLD appendix (pgs 10, 28-29) |
| 14 | State how analytic or statistical source code used to generate estimates can be accessed. | Access statement provided in methods | Main text (Methods) Code is provided in an online repository https://github.com/ihmeuw/ihme-modeling |

| Res | ults and Discussion | | |
|-----|--|---|---|
| 15 | Provide published estimates in a file format from which data can be efficiently extracted. | GBD 2016 results are available through online data visualisation tools, the Global Health Data Exchange, and the online data query tool | Main text and online data tools (data visualisation tools, data query tools, and the Global Health Data Exchange) www.healthdata.org /results/data- visualizations; http://ghdx.healthdata.org/gb-results- tool; http://ghdx.healthdata.org/ |
| 16 | Report a quantitative measure of the uncertainty of the estimates (eg, uncertainty intervals). | Uncertainty intervals are provided with all results | Main text (Methods, results), methods appendix and online data tools (data visualisation tools, data query tools, and the Global Health Data Exchange) www.healthdata.org /results/data-visualizations; http://ghdx.healthdata.org/gb-results-tool; http://ghdx.healthdata.org/ |
| 17 | Interpret results in light of existing evidence. If updating a previous set of estimates, describe the reasons for changes in estimates. | Discussion of methodological changes between GBD rounds provided in the research in context section of the paper | Research in context |
| 18 | Discuss limitations of the estimates. Include a discussion of any modelling assumptions or data limitations that affect interpretation of the estimates. | Discussion of limitations provided in the narrative of the paper | Main text (Discussion, limitations) |

^{*}Gakidou E, Afshin A, Abajobir AA, et al. Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990–2016: a

systematic analysis for the Global Burden of Disease Study 2016. The Lancet 2017; 390: 1345–422.

**Supplementary appendix 1

*Hay SI, Abajobir AA, Abate KH, et al. Global, regional, and national disability-adjusted life-years (DALYs) for 333 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. The Lancet 2017; 390: 1260–344.

** Supplementary appendix 1

*Naghavi M, Abajobir AA, Abbafati C, et al. Global, regional, and national age-sex specific mortality for 264 causes of death, 1980–2016: a systematic analysis for the Global Burden of Disease Study 2016. The Lancet 2017; 390: 1151–210.

** Supplementary appendix 1

*Vos T, Abajobir AA, Abate KH, et al. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. The Lancet 2017; 390: 1211–59.

** Supplementary appendix 1

*Wang H, Abajobir AA, Abate KH, et al. Global, regional, and national under-5 mortality, adult mortality, age-specific mortality, and life expectancy, 1970–2016: a systematic analysis for the Global Burden of Disease Study 2016. The Lancet 2017; 390: 1084–150.

** Supplementary appendix 1

| Appendix ' | Table 2. Total number of site ye | ars* by cause an | d source type, ca | ause of death est | imates 1990-201 | 6 Indonesia | | |
|------------|---|--------------------|-------------------|-------------------|-----------------|---------------|-----------------|----------------|
| Level | Cause | Vital Registration | Verbal Autopsy | Surveillance | Sibling History | Survey/Census | Cancer Registry | Police Records |
| 0 | All causes | | 150 | | 805 | 233 | | 3 |
| 1 | Communicable, maternal, neonatal, and nutritional diseases | | 134 | | 805 | 214 | | |
| 2 | HIV/AIDS and tuberculosis | | 113 | | | | | |
| 3 | Tuberculosis | | 110 | | | | | |
| 4 | Drug-susceptible tuberculosis | | | | | | | |
| 4 | Multidrug-resistant tuberculosis without extensive drug resistance | | | | | | | |
| 4 | Extensively drug-resistant tuberculosis | | | | | | | |
| 3 | HIV/AIDS | | 83 | | | | | |
| 4 | Drug-susceptible HIV/AIDS - Tuberculosis | | | | | | | |
| 4 | Multidrug-resistant HIV/AIDS - Tuberculosis without extensive drug resistance | | | | | | | |
| 4 | Extensively drug-resistant HIV/AIDS - Tuberculosis | | | | | | | |
| 4 | HIV/AIDS resulting in other diseases | | | | | | | |
| 2 | Diarrhea, lower respiratory, and other common infectious diseases | | 115 | | | | | |
| 3 | Diarrheal diseases | | 104 | | | | | |
| 3 | Intestinal infectious diseases | | 90 | | | | | |
| 4 | Typhoid fever | | | | | | | |
| 4 | Paratyphoid fever | | | | | | | |
| 4 | Other intestinal infectious diseases | | | | | | | |
| 3 | Lower respiratory infections | | 105 | | | | | |
| 3 | Upper respiratory infections | | | | | | | |
| 3 | Otitis media | | 56 | | | | | |
| 3 | Meningitis | | 85 | | | | | |
| 4 | Pneumococcal meningitis | | | | | | | |
| 4 | H influenzae type B meningitis | | | | | | | |
| 4 | Meningococcal meningitis | | | | | | | |
| 4 | Other meningitis | | | | | | | |
| 3 | Encephalitis | | 83 | | | | | |
| 3 | Diphtheria | | | | | | | |
| 3 | Whooping cough | | | | | | | |

| 3 | Tetanus | 76 | | | | |
|---|---|----|-----|-----|--|--|
| 3 | Measles | 58 | | | | |
| 3 | Varicella and herpes zoster | | | | | |
| 2 | Neglected tropical diseases and malaria | 96 | | | | |
| 3 | Malaria | 81 | | | | |
| 3 | Chagas disease | | | | | |
| 3 | Leishmaniasis | 67 | | | | |
| 4 | Visceral leishmaniasis | 67 | | | | |
| 3 | African trypanosomiasis | 63 | | | | |
| 3 | Schistosomiasis | | | | | |
| 3 | Cysticercosis | | | | | |
| 3 | Cystic echinococcosis | | | | | |
| 3 | Dengue | 80 | | | | |
| 3 | Yellow fever | 69 | | | | |
| 3 | Rabies | 71 | | | | |
| 3 | Intestinal nematode infections | 70 | | | | |
| 4 | Ascariasis | | | | | |
| 3 | Ebola virus disease | | | | | |
| 3 | Zika virus disease | | | | | |
| 3 | Other neglected tropical diseases | | | | | |
| 2 | Maternal disorders | 64 | 805 | 187 | | |
| 3 | Maternal haemorrhage | 38 | | | | |
| 3 | Maternal sepsis and other maternal infections | 28 | | | | |
| 3 | Maternal hypertensive disorders | 42 | | | | |
| 3 | Maternal obstructed labor and uterine | 72 | | | | |
| 3 | rupture | 21 | | | | |
| 3 | Maternal abortion, miscarriage, and ectopic pregnancy | 32 | | | | |
| 3 | Indirect maternal deaths | 31 | | | | |
| 3 | Late maternal deaths | | | _ | | |
| 3 | Maternal deaths aggravated by HIV/AIDS | 64 | 805 | 187 | | |
| 3 | Other maternal disorders | | | | | |
| 2 | Neonatal disorders | 59 | | | | |
| 3 | Neonatal preterm birth complications | 44 | | | | |

| | Neonatal encephalopathy due to birth | | | | |
|---|--|-----|--|--|--|
| 3 | asphyxia and trauma Neonatal sepsis and other neonatal | 45 | | | |
| 3 | infections | | | | |
| 3 | Hemolytic disease and other neonatal jaundice | | | | |
| 3 | Other neonatal disorders | | | | |
| 2 | Nutritional deficiencies | 77 | | | |
| 3 | Protein-energy malnutrition | 74 | | | |
| 3 | Iodine deficiency | | | | |
| 3 | Iron-deficiency anemia | 56 | | | |
| 3 | Other nutritional deficiencies | | | | |
| 2 | Other communicable, maternal, neonatal, and nutritional diseases | 97 | | | |
| 3 | Sexually transmitted diseases excluding HIV | 75 | | | |
| 4 | Syphilis | 73 | | | |
| 4 | Chlamydial infection | | | | |
| 4 | Gonococcal infection | | | | |
| 4 | Other sexually transmitted diseases | | | | |
| 3 | Hepatitis | 84 | | | |
| 4 | Acute hepatitis A | | | | |
| 4 | Hepatitis B | | | | |
| 4 | Hepatitis C | | | | |
| 4 | Acute hepatitis E | | | | |
| 3 | Other infectious diseases | 87 | | | |
| 1 | Non-communicable diseases | 135 | | | |
| 2 | Neoplasms | 108 | | | |
| 3 | Lip and oral cavity cancer | 70 | | | |
| 3 | Nasopharynx cancer | | | | |
| 3 | Other pharynx cancer | | | | |
| 3 | Esophageal cancer | 68 | | | |
| 3 | Stomach cancer | | | | |
| 3 | Colon and rectum cancer | 78 | | | |
| 3 | Liver cancer | | | | |
| 4 | Liver cancer due to hepatitis B | | | | |
| 4 | Liver cancer due to hepatitis C | | | | |

| 4 | Liver cancer due to alcohol use | | • | • | |
|---|--|-----|---|---|--|
| 4 | Liver cancer due to other causes | | | | |
| 3 | Gallbladder and biliary tract cancer | | | | |
| 3 | Pancreatic cancer | | | | |
| 3 | Larynx cancer | | | | |
| 3 | Tracheal, bronchus, and lung cancer | 70 | | | |
| 3 | Malignant skin melanoma | | | | |
| 3 | Non-melanoma skin cancer | | | | |
| 4 | Non-melanoma skin cancer (squamous- cell carcinoma) | | | | |
| 3 | Breast cancer | 74 | | | |
| 3 | Cervical cancer | | | | |
| 3 | Uterine cancer | | | | |
| 3 | Ovarian cancer | | | | |
| 3 | Prostate cancer | | | | |
| 3 | Testicular cancer | 40 | | | |
| 3 | Kidney cancer | | | | |
| 3 | Bladder cancer | | | | |
| 3 | Brain and nervous system cancer | | | | |
| 3 | Thyroid cancer | | | | |
| 3 | Mesothelioma | | | | |
| 3 | Hodgkin's lymphoma | | | | |
| 3 | Non-Hodgkin lymphoma | | | | |
| 3 | Multiple myeloma | | | | |
| 3 | Leukaemia | 78 | | | |
| 4 | Acute lymphoid leukaemia | | | | |
| 4 | Chronic lymphoid leukaemia | | | | |
| 4 | Acute myeloid leukaemia | | | | |
| 4 | Chronic myeloid leukaemia | | | | |
| 4 | Other leukaemia | 78 | | | |
| 3 | Other neoplasms | | | | |
| 2 | Cardiovascular diseases | 123 | | | |
| 3 | Rheumatic heart disease | | | | |
| 3 | Ischaemic heart disease | 103 | | | |
| 3 | Cerebrovascular disease | 106 | | | |

| 4 | Ischaemic stroke | | 1 | | 1 |
|---|--|-----|---|--|---|
| 4 | Haemorrhagic stroke | | | | |
| 3 | Hypertensive heart disease | | | | |
| 3 | Cardiomyopathy and myocarditis | | | | |
| 4 | Myocarditis | | | | |
| 4 | Alcoholic cardiomyopathy | | | | |
| 4 | Other cardiomyopathy | | | | |
| 3 | Atrial fibrillation and flutter | | | | |
| 3 | Aortic aneurysm | | | | |
| 3 | Peripheral artery disease | | | | |
| 3 | Endocarditis | | | | |
| 3 | Other cardiovascular and circulatory diseases | | | | |
| 2 | Chronic respiratory diseases | 109 | | | |
| 3 | Chronic obstructive pulmonary disease | | | | |
| 3 | Pneumoconiosis | | | | |
| 4 | Silicosis | | | | |
| 4 | Asbestosis | | | | |
| 4 | Coal workers pneumoconiosis | | | | |
| 4 | Other pneumoconiosis | | | | |
| 3 | Asthma | | | | |
| 3 | Interstitial lung disease and pulmonary sarcoidosis | | | | |
| 3 | Other chronic respiratory diseases | | | | |
| 2 | Cirrhosis and other chronic liver diseases | 97 | | | |
| 3 | Cirrhosis and other chronic liver diseases due to hepatitis B | | | | |
| 3 | Cirrhosis and other chronic liver diseases due to hepatitis C | | | | |
| 3 | Cirrhosis and other chronic liver diseases due to alcohol use | | | | |
| 3 | Cirrhosis and other chronic liver diseases due to other causes | | | | |
| 2 | Digestive diseases | 102 | | | |
| 3 | Peptic ulcer disease | | | | |
| 3 | Gastritis and duodenitis | | | | |
| 3 | Appendicitis | | | | |

| 3 | Paralytic ileus and intestinal obstruction | 67 | | | |
|---|---|-----|--|--|--|
| 3 | Inguinal, femoral, and abdominal hernia | 55 | | | |
| 3 | Inflammatory bowel disease | | | | |
| 3 | Vascular intestinal disorders | | | | |
| 3 | Gallbladder and biliary diseases | | | | |
| 3 | Pancreatitis | | | | |
| 3 | Other digestive diseases | | | | |
| 2 | Neurological disorders | 65 | | | |
| 3 | Alzheimer's disease and other dementias | | | | |
| 3 | Parkinson's disease | | | | |
| 3 | Epilepsy | 38 | | | |
| 3 | Multiple sclerosis | | | | |
| 3 | Motor neuron disease | | | | |
| 3 | Other neurological disorders | | | | |
| 2 | Mental and substance use disorders | 46 | | | |
| 3 | Alcohol use disorders | 46 | | | |
| 3 | Drug use disorders | 43 | | | |
| 4 | Opioid use disorders | | | | |
| 4 | Cocaine use disorders | | | | |
| 4 | Amphetamine use disorders | | | | |
| 4 | Other drug use disorders | | | | |
| 3 | Eating disorders | | | | |
| 4 | Anorexia nervosa | | | | |
| 4 | Bulimia nervosa | | | | |
| 2 | Diabetes, urogenital, blood, and endocrine diseases | 111 | | | |
| 3 | Diabetes mellitus | 96 | | | |
| 3 | Acute glomerulonephritis | 70 | | | |
| 3 | Chronic kidney disease | 102 | | | |
| | Chronic kidney disease due to diabetes | 102 | | | |
| 4 | mellitus | | | | |
| 4 | hypertension Chronic kidney disease due to | | | | |
| 4 | Chronic kidney disease due to glomerulonephritis | | | | |
| 4 | causes | | | | |
| 3 | Urinary diseases and male infertility | 84 | | | |

| 4 | Interstitial nephritis and urinary tract infections | | | | |
|---|---|----|---|--|--|
| 4 | Urolithiasis | | | | |
| 4 | Other urinary diseases | | | | |
| 3 | Gynecological diseases | 51 | | | |
| 4 | Uterine fibroids | | | | |
| 4 | Polycystic ovarian syndrome | | | | |
| 4 | Endometriosis | | | | |
| 4 | Genital prolapse | | | | |
| 4 | Other gynaecological diseases | | | | |
| | Haemoglobinopathies and hemolytic anaemias | 20 | | | |
| 3 | Thalassaemias | 90 | | | |
| 4 | Sickle cell disorders | 87 | | | |
| 4 | G6PD deficiency | 87 | | | |
| 4 | Other haemoglobinopathies and | | | | |
| 4 | hemolytic anaemias | | | | |
| 3 | Endocrine, metabolic, blood, and immune disorders | 88 | | | |
| 2 | Musculoskeletal disorders | 00 | | | |
| 3 | Rheumatoid arthritis | | | | |
| 3 | Other musculoskeletal disorders | | | | |
| 2 | Other non-communicable diseases | 97 | | | |
| 3 | Congenital birth defects | 82 | | | |
| 4 | Neural tube defects | 82 | | | |
| 4 | Congenital heart anomalies | | | | |
| 4 | Orofacial clefts | | | | |
| 4 | Down syndrome | | | | |
| 4 | Other chromosomal abnormalities | | | | |
| , | Congenital musculoskeletal and limb | | _ | | |
| 4 | anomalies | | | | |
| 4 | Urogenital congenital anomalies | | | | |
| 4 | Digestive congenital anomalies | | | | |
| 4 | Other congenital birth defects | | | | |
| 3 | Skin and subcutaneous diseases | 85 | | | |
| 4 | Cellulitis | | | | |
| 4 | Pyoderma | | | | |

| 4 | Decubitus ulcer | | | | |
|---|---|--------|--|-----|------|
| 4 | Other skin and subcutaneous diseases | | | | |
| 3 | Sudden infant death syndrome | | | | |
| 1 | Injuries | 117 | | 233 | 3 |
| 2 | Transport injuries | 108 | | 229 | 1 |
| 3 | Road injuries | | | | 1 |
| 4 | Pedestrian road injuries | | | | 1 |
| 4 | Cyclist road injuries | | | | 1 |
| 4 | Motorcyclist road injuries | | | | 1 |
| 4 | Motor vehicle road injuries | | | | 1 |
| 4 | Other road injuries | | | | 1 |
| 3 | Other transport injuries | | | | |
| 2 | Unintentional injuries | 102 | | | |
| 3 | Falls | 90 | | | |
| 3 | Drowning | 76 | | | |
| 3 | Fire, heat, and hot substances | 74 | | | |
| 3 | Poisonings | 64 | | | |
| 3 | Exposure to mechanical forces | 81 | | | |
| 4 | Unintentional firearm injuries | 70 | | | |
| 4 | Unintentional suffocation | 52 | | | |
| 4 | Other exposure to mechanical forces | 80 | | | |
| 3 | Adverse effects of medical treatment | | | | |
| 3 | Animal contact | 65 | | | |
| 4 | Venomous animal contact | 55 | | | |
| 4 | Non-venomous animal contact | | | | |
| 3 | Foreign body | 79 | | | |
| 4 | Pulmonary aspiration and foreign body in airway | | | | |
| 4 | Foreign body in other body part | | | | |
| 3 | Environmental heat and cold exposure | 65 | | | |
| 3 | Other unintentional injuries | | | | |
| 2 | Self-harm and interpersonal violence | 84 | | | 2 |
| | Self-harm | 88 | | | 2 |
| 3 | Self-harm by firearm | 77 | | | |
| 4 | Self-harm by other specified means | | | | |
| 4 | Sen-harm by other specified means | | | | |

| 3 | Interpersonal violence | 79 | | | 2 |
|---|--|----|--|--|---|
| 4 | Physical violence by firearm | 64 | | | |
| 4 | Physical violence by sharp object | 73 | | | |
| 4 | Physical violence by other means | 70 | | | |
| 2 | Forces of nature, conflict and terrorism, and executions and police conflict | 59 | | | |
| 3 | Exposure to forces of nature | 54 | | | |
| 3 | Conflict and terrorism | 56 | | | |
| 3 | Executions and police conflict | 49 | | | |

^{*}A site year for a disease indicates that data were collected on that disease, not that there were incident cases in that site year. Some diseases may have site year data but zero cases of disease.

Methods

The GBD 2016 study organises causes of mortality and morbidity within a four-level classification hierarchy to produce estimates that are mutually exclusive and collectively exhaustive. The full GBD cause hierarchy, including corresponding International Classification of Diseases (ICD)-9 and ICD-10 codes, is detailed in the respective GBD 2016 publications. Risk factors are likewise organised in a four-tier hierarchy. Additional details on GBD metrics and definitions are found elsewhere.

1. Data

Table 2 shows the data sources included in the estimation process from Indonesia for mortality and morbidity by cause. For GBD 2016 a star ranking system from 0 to 5 was developed to assess data quality in each location. Indonesia received 2 stars in 2016, with 14.5% well certified data for the period 1980-2016 and 56.7% for 2010-2016.

2. Mortality

We report data on cause-specific mortality and cause-specific years of life lost due to premature mortality (years of life lost, YLLs) for 264 causes of mortality by age and sex. ^{17,22} Cause-specific mortality estimates for each age, sex, and location-year were generated using the GBD Cause of Death Ensemble model (CODEm) and the CodCorrect process. In CODEm, a variety of models were developed. For each individual model, out-of-sample predictive validity was assessed and models were ranked for use in ensemble modelling. The ensemble with the highest out-of-sample predictive validity was selected from differently weighted combinations of individual models. For causes where there was evidence that children and adults had different relationships between their covariates and death rates, separate models were run for different age ranges. Separate models were also developed for countries with complete, representative, and extensive VR by cause to ensure that uncertainty reflects the more complete data in those locations. The CoDCorrect process ensures that there is internal consistency between cause-specific and all-cause mortality estimates by rescaling causes up the GBD hierarchy using a core algorithm.

3. Morbidity

Estimates of morbidity were produced for 328 causes and 2,982 sequela for each age, sex, and year. For GBD 2016, 68 causes were considered causes of disability but not death, while five were considered causes of death but not disability. To estimate years of life lived with disability (YLDs), the Bayesian meta-regression tool DisMod-MR 2.1 estimated prevalence and incidence for most causes of disease and injury and their non-fatal outcomes, calculated the product of incidence and a specific disability weight for each sequela, adjusted for comorbidity, and aggregated to cause-level, ensuring consistency for each condition. Several causes were estimated using custom models; details of these causes and their modelling strategy can be found in the GBD YLDs publication. YLDs were estimated for all mutually exclusive sequelae by multiplying prevalence by a disability weight, then correcting for comorbidity and aggregating to cause level.

4. SDI

The SDI is a summary indicator based on average lag-dependent income per capita, total fertility rate in the population, and years of education attained in the population over 15 years of age, calculated as the geometric mean of the rescaled (0-1) values of the three components for each location-year. GBD 2016 grouped locations into quintiles of low, low-middle, middle, high-middle, and high SDI for analysis.

Expected values calculation

Gaussian process regression using a linear prior to the mean function within a stochastic partial differential equation (SPDE) framework was used to estimate the relationship between SDI and each age-sex-cause death rate. These relationships were used to estimate expected YLLs based on SDI alone for each age, sex, location, and year.

Scale of SDI


For each component of the SDI, 0 represents a theoretical minimum level of development for the selected health outcomes and 1 represents a theoretical maximum level of development for the selected health outcomes. Thresholds were set based on the relationship between each component with under-5 mortality rates and life expectancy at birth and identified points of limiting returns if they occurred prior to theoretical limits.


Supplemental figures


SI Figure 1. Attribution of changes in under-5 mortality for Indonesia and comparator countries to changes in major groups of causes of death, 1990–2016

Changes are shown for Indonesia and comparator countries for both sexes combined. Locations are ordered by decreasing under-5 mortality in 2016. Purple lines show under-5 mortality rate in 1990 and black lines show under-5 mortality rate in in 2016. Causes to the left of the 1990 under-5 mortality values reflect causes that contributed to reductions in under-5 mortality rate from 1990 to 2015. Causes to the right of the 1990 under-5 mortality values contributed to increases in under-5 mortality rate from 1990 to 2015.

CMNN=communicable, maternal, neonatal & nutritional causes. NCDs=non-communicable diseases.







SI Figure 2. Leading 30 Level 3 causes of mortality in Indonesia for 1990, 2006, and 2016, with percent change in number of mortalities, and all-age and age-standardised mortality rates

Causes are ordered by total deaths and are connected by arrows between time periods. Communicable, maternal, neonatal, and nutritional disorders are shown in red, non-communicable causes in blue, and injuries in green. For the time period 1990 to 2006 and for 2006 to 2015, three measures of change are shown: median percent change in the number of mortalities, median percent change in the all-age mortality rate, and median percent change in the age-standardised mortality rate. Median values across the 1,000 draws from the uncertainty distribution are shown. Both sexes combined. COPD=chronic obstructive pulmonary disease.

Top 30 Level 3 causes of deaths for 1990, 2006, and 2016, Indonesia, both sexes


Causes are connected by arrows between time periods. Communicable, maternal, neonatal, and nutritional disorders are shown in red, non-communicable causes in blue and injuries in green. For the time period 1990 to 2016, three measures of change are shown: percent change in the number of deaths, percent change in the all-age death rate, and percent change in the age-standardised death rate. Numbers in bold highlight statistically significant changes.

| Leading causes 1990 | Leading causes 2006 | Mean % change number of deaths 1990-2006 | Mean % change all-age death rate 1990-2006 | Mean % change age- standardised death rate 1990-2006 | | Leading causes 2016 | Mean % change number of deaths 2006-2016 | Mean % change all-age death rate 2006-2016 | Mean % change age- standardised death rate 2006-2016 |
|--|-----------------------------------|--|--|--|---------------|-----------------------------------|--|--|--|
| 1 Diarrhoeal diseases | 1 Ischaemic heart disease | 63.6% | 27.5% | 6.6% | | 1 Ischaemic heart disease | 11.3% | -0.5% | -12.7% |
| 2 Tuberculosis | 2 Cerebrovascular disease | 66.1% | 29.5% | 5.7% | | 2 Cerebrovascular disease | 32.2% | 18.2% | 0.5% |
| 3 Ischaemic heart disease | 3 Tuberculosis | -20.7% | -38.2% | -46.4% | | 3 Tuberculosis | -26.5% | -34.2% | -41.2% |
| 4 Cerebrovascular disease | 4 Diarrhoeal diseases | -56.2% | -65.9% | -63.1% | | 4 Diabetes | 54.2% | 37.9% | 16.5% |
| 5 Lower respiratory infections | 5 Diabetes | 98.0% | 54.3% | 29.7% | | 5 COPD | 14.9% | 2.8% | -11.9% |
| 6 Neonatal preterm birth complications | 6 Lower respiratory infections | -37.9% | -51.6% | -38.1% | | 6 Diarrhoeal diseases | -28.2% | -35.8% | -31.7% |
| 7 Road injuries | 7 COPD | 54.0% | 20.0% | -4.1% | | 7 Alzheimer's disease | 40.1% | 25.3% | 9.2% |
| 8 Neonatal encephalopathy | 8 Road injuries | 5.7% | -17.6% | -22.1% | | 8 Road injuries | -4.9% | -14.9% | -23.1% |
| 9 Measles | 9 Neonatal preterm birth complice | | -39.0% | -29.3% | | 9 Lower respiratory infections | -32.8% | -39.9% | -29.4% |
| 10 Diabetes | 10 Asthma | 14.7% | -10.6% | -24.7% | | 10 Chronic kidney disease | 16.1% | 3.9% | -11.8% |
| 11 Asthma | 11 Alzheimer's disease | 103.1% | 58.3% | 21.5% | | 11 Asthma | -1.9% | -12.3% | -23.6% |
| 12 COPD | 12 Chronic kidney disease | 64.1% | 27.9% | 9.9% | | 12 Hypertensive heart disease | 5.2% | -5.9% | -16.0% |
| 13 Congenital defects | 13 Hypertensive heart disease | 31.1% | 2.1% | -13.5% | `` | 13 Neonatal preterm birth compl | cati 36.8 % | -43.5% | -29.0% |
| 14 Hypertensive heart disease | 14 Neonatal encephalopathy | -19.7% | -37.5% | -27.5% | | 14 Peptic ulcer disease | -2.2% | -12.5% | -21.5% |
| 15 Tetanus | 15 Peptic ulcer disease | 19.1% | -7.2% | -19.4% | | 15 Neonatal encephalopathy | -39.5% | -45.9% | -32.0% |
| 16 Peptic ulcer disease | 16 Congenital defects | -10.6% | -30.3% | -20.4% | | 16 Breast cancer | 19.1% | 6.5% | -9.7% |
| 17 Chronic kidney disease | 17 Falls | 29.2% | 0.7% | -10.0% | | 17 Falls | -0.4% | -11.0% | -19.2% |
| 18 Intestinal infectious diseases | 18 Cirrhosis other | 40.0% | 9.1% | 1.5% | \rightarrow | 18 Cirrhosis other | 4.3% | -6.7% | -15.6% |
| 19 Alzheimer's disease | 19 Breast cancer | 62.7% | 26.8% | 6.7% | | 19 Ileus & obstruction | 12.3% | 0.4% | -1.8% |
| 20 Rheumatic heart disease | 20 Ileus & obstruction | 37.2% | 6.9% | 9.5% | | 20 Protein-energy malnutrition | 12.7% | 0.8% | -1.7% |
| 21 Falls | 21 Protein-energy malnutrition | 13.7% | -11.4% | -12.7% | · ` | 21 Congenital defects | -33.6% | -40.7% | -28.1% |
| 22 Drowning | 22 Other cardiovascular disease | s 33.4% | 3.9% | -6.5% | · | 22 Cirrhosis due to hepatitis B | 13.6% | 1.6% | -11.9% |
| 23 Protein-energy malnutrition | 23 Intestinal infectious diseases | -29.3% | -44.9% | -38.8% | | 23 Other cardiovascular disease | s 5.2% | -5.9% | -13.8% |
| 24 Cirrhosis other | 24 Cirrhosis due to hepatitis B | 61.4% | 25.8% | 5.2% | | 24 Lung cancer | 19.4% | 6.8% | -9.6% |
| 25 Ileus & obstruction | 25 Stomach cancer | 34.0% | 4.4% | -11.5% | | 25 Cirrhosis due to alcohol | 16.0% | 3.7% | -11.4% |
| 26 Other cardiovascular diseases | 26 Lung cancer | 55.5% | 21.2% | 0.6% | | 26 Stomach cancer | 12.7% | 0.8% | -12.1% |
| 27 Malaria | 27 Cirrhosis due to alcohol | 68.9% | 31.6% | 9.4% | ` | 27 Intestinal infectious diseases | -8.6% | -18.2% | -12.8% |
| 28 Neonatal sepsis | 28 Rheumatic heart disease | -23.4% | -40.3% | -44.2% | | 28 Colorectal cancer | 23.9% | 10.8% | -3.9% |
| 29 Breast cancer | 29 Drowning | -16.6% | -35.0% | -27.6% | | 29 Cirrhosis due to hepatitis C | 11.6% | -0.2% | -14.2% |
| 30 Meningitis | 30 Cirrhosis due to hepatitis C | 50.2% | 17.0% | -1.5% | | 30 Other neoplasms | 28.0% | 14.5% | 3.9% |
| 31 Stomach cancer | 31 Colorectal cancer | | | | | 35 Rheumatic heart disease | | | |
| 33 Cirrhosis due to hepatitis B | 33 Other neoplasms | | | | | 36 Drowning | | | |
| 37 Lung cancer | 38 Neonatal sepsis | | | | / | ·48 Malaria | | Legend: | |
| 38 Cirrhosis due to hepatitis C | 40 Meningitis | | | | | 49 Neonatal sepsis | | Communicab | le, maternal, |
| 39 Cirrhosis due to alcohol | 41 Measles | | | | | 52 Meningitis | | neonatal, and | |
| 43 Colorectal cancer | 43 Tetanus | | | | | 59 Measles | | Non-commun | icable |
| 46 Other neoplasms | 44 Malaria | | | | / | 76 Tetanus | | Injuries | |


SI Figure 3. Age-standardised rates of YLLs for males versus females in Indonesia and comparator countries, (A) 1990, (B) 2016

YLLs=years of life lost. HIV/AIDS=human immunodeficiency virus/acquired immunodeficiency syndrome.

Age-standardised YLLs by Level 2 GBD cause, 1990



Age-standardised YLLs by Level 2 GBD cause,



SI Figure 4. Leading 30 Level 3 causes of YLLs in Indonesia for 1990, 2006, and 2016, with percent change in number of YLLs, and all-age and age-standardised YLL rates

Causes are ordered by total YLLs and are connected by arrows between time periods. Communicable, maternal, neonatal, and nutritional disorders are shown in red, non-communicable causes in blue, and injuries in green. For the time period 1990 to 2006 and for 2006 to 2015, three measures of change are shown: median percent change in the number of YLLs, median percent change in the all-age YLL rate, and median percent change in the age-standardised YLL rate. Median values across the 1,000 draws from the uncertainty distribution are shown. Both sexes combined. YLLs=years of life lost. COPD=chronic obstructive pulmonary disease. STDs=sexually transmitted diseases. HIV/AIDS=human immunodeficiency virus/acquired immunodeficiency syndrome.

Top 30 Level 3 causes of YLLs for 1990, 2006, and 2016, Indonesia, both sexes

Causes are connected by arrows between time periods. Communicable, maternal, neonatal, and nutritional disorders are shown in red, non-communicable causes in blue, and injuries in green. For the time period 1990 to 2016, three measures of change are shown: percent change in the number of YLLs, percent change in the all-age YLL rate, and percent change in the age-standardised YLL rate. Numbers in bold highlight statistically significant changes.

| Leading causes 1990 | Leading causes 2006 | Mean % change number of YLLs 1990-2006 | Mean % change all-age YLL rate 1990-2006 | Mean % change age- standardised YLL rate 1990-2006 | ı | | Mean % change number of YLLs 2006-2016 | Mean % change all-age YLL rate 2006-2016 | Mean % change age- standardise MLL rate 2006-2016 |
|--|-----------------------------------|--|--|--|------------------|-----------------------------------|--|--|---|
| 1 Diarrhoeal diseases | 1 Ischaemic heart disease | 56.6% | 22.0% | 3.4% | | 1 Ischaemic heart disease | 9.8% | -1.8% | -15.3% |
| 2 Lower respiratory infections | 2 Tuberculosis | -27.1% | -43.2% | -48.3% | ļ. <u>.</u> | 2 Cerebrovascular disease | 29.3% | 15.7% | 0.6% |
| 3 Tuberculosis | 3 Cerebrovascular disease | 54.5% | 20.4% | 4.4% | | 3 Tuberculosis | -30.3% | -37.6% | -41.9% |
| 4 Neonatal preterm birth complications | 4 Lower respiratory infections | -49.5% | -60.6% | -53.7% | 1. | 4 Diabetes | 54.3% | 38.0% | 16.3% |
| 5 Ischaemic heart disease | 5 Neonatal preterm birth complic | | -39.0% | -29.3% | | 5 Neonatal preterm birth complic | | -43.5% | -28.9% |
| 6 Neonatal encephalopathy | 6 Diarrhoeal diseases | -65.9% | -73.5% | -69.8% | i. `\/ | 6 Road injuries | -6.5% | -16.4% | -18.2% |
| 7 Measles | 7 Neonatal encephalopathy | -19.7% | -37.5% | -27.5% | | 7 Lower respiratory infections | -50.0% | -55.3% | -46.6% |
| 8 Cerebrovascular disease | 8 Road injuries | -6.7% | -27.3% | -25.4% | / / | 8 Diarrhoeal diseases | -48.6% | -54.0% | -46.9% |
| 9 Road injuries | 9 Congenital defects | -11.3% | -30.9% | -20.9% | 1-/ | 9 Neonatal encephalopathy | -39.5% | -45.9% | -32.0% |
| 10 Congenital defects | 10 Diabetes | 89.5% | 47.7% | 27.5% | | 10 Congenital defects | -34.3% | -41.3% | -28.3% |
| 11 Tetanus | 11 Chronic kidney disease | 50.1% | 17.0% | 6.5% | † | 11 Chronic kidney disease | 14.3% | 2.2% | -8.9% |
| 12 Intestinal infectious diseases | 12 Intestinal infectious diseases | -30.6% | -45.9% | -38.0% | ر ا | 12 COPD | 14.6% | 2.5% | -11.1% |
| 13 Drowning | 13 Asthma | 3.4% | -19.4% | -26.6% | | 13 Asthma | -5.7% | -15.6% | -24.7% |
| 14 Asthma | 14 COPD | 47.0% | 14.5% | -4.1% | | 14 Intestinal infectious diseases | -11.4% | -20.7% | -14.1% |
| 15 Diabetes | 15 Drowning | -24.3% | -41.0% | -34.0% | i _ | 15 Hypertensive heart disease | 2.7% | -8.2% | -20.1% |
| 16 Neonatal sepsis | 16 Hypertensive heart disease | 23.7% | -3.6% | -17.5% | | 16 Breast cancer | 18.4% | 5.9% | -10.5% |
| 17 Other neonatal | 17 Neonatal sepsis | -18.0% | -36.1% | -26.1% | i \ / | 17 Alzheimer's disease | 37.6% | 23.1% | 7.6% |
| 18 Meningitis | 18 Other neonatal disorders | -16.1% | -34.6% | -24.4% | i\ \ /4 | 18 Cirrhosis other | -2.0% | -12.4% | -17.9% |
| 19 Chronic kidney disease | 19 Ileus & obstruction | 6.0% | -17.4% | -7.6% | | 19 Ileus & obstruction | -9.9% | -19.4% | -13.4% |
| 20 STDs | 20 Cirrhosis other | 21.4% | -5.4% | -7.1% | | 20 Peptic ulcer disease | -7.6% | -17.4% | -25.2% |
| 21 Rheumatic heart disease | 21 Peptic ulcer disease | 4.6% | -18.4% | -25.5% | | 21 Falls | -7.6% | -17.3% | -21.0% |
| 22 COPD | 22 Measles | -81.1% | -85.3% | -83.3% | | 22 Drowning | -29.3% | -36.8% | -31.8% |
| 23 Malaria | 23 Falls | 11.9% | -12.8% | -15.8% | | 23 Cirrhosis due to hepatitis B | 10.7% | -1.0% | -13.6% |
| 24 Ileus & obstruction | 24 Meningitis | -28.4% | -44.2% | -37.3% | iX/\ / | 24 Neonatal sepsis | -31.9% | -39.0% | -23.4% |
| 25 Peptic ulcer disease | 25 Breast cancer | 60.6% | 25.1% | 3.7% | XX V_ | 25 Self-harm | 0.5% | -10.1% | -10.6% |
| 26 Hypertensive heart disease | 26 Self-harm | 31.3% | 2.3% | -3.8% | AX | 26 HIV/AIDS | 132.5% | 107.9% | 103.8% |
| 27 Cirrhosis other | 27 Alzheimer's disease | 90.2% | 48.2% | 19.1% | YX\\\ | 27 Cirrhosis due to alcohol | 13.9% | 1.9% | -13.0% |
| 28 Falls | 28 Cirrhosis due to hepatitis B | 58.8% | 23.8% | 2.8% | | 28 Other neoplasms | 18.0% | 5.5% | -0.2% |
| 29 Protein-energy malnutrition | 29 Rheumatic heart disease | -33.2% | -48.0% | -49.0% | | 29 Dengue | 31.1% | 17.2% | 30.3% |
| 30 Whooping cough | 30 Other cardiovascular | 14.2% | -11.0% | -14.2% | | 30 Other cardiovascular disease | -3.9% | -14.1% | -19.2% |
| 34 Other cardiovascular diseases | -31 Whooping cough | | | | \ <i>X</i> \//X\ | 31 Other neonatal disorders | | | |
| 36 Self-harm | 33 Cirrhosis due to alcohol | | | | $\times/\%$ | 34 Measles | | | |
| 37 Breast cancer | 34 Protein-energy malnutrition | | | | | 38 Meningitis | | Legend: | |
| 38 Cirrhosis due to hepatitis B | 35 Other neoplasms | | | | / /- · | 40 Rheumatic heart disease | | Communicab | le, maternal, |
| 41 Alzheimer's disease | 37 Tetanus | | | | | 41 Protein-energy malnutrition | | neonatal, and | I nutritional |
| 44 Dengue | 38 STDs | | | | XX X | 47 Malaria | | Non-commun | icable |
| 48 Other neoplasms | 42 Dengue | | | | 17 | 48 Whooping cough | | Injuries | |
| 49 Cirrhosis due to alcohol | 43 Malaria | | | | + | 56 STDs | | | |
| 137 HIV/AIDS | -60 HIV/AIDS | | 27 | | / | 69 Tetanus | | | |
| | | | | | | | | | |

SI Figure 5. Leading 30 Level 3 causes of YLDs in Indonesia for 1990, 2006, and 2016, with percent change in number of YLDs, and all-age and age-standardised YLD rates

Causes are ordered by total YLDs and are connected by arrows between time periods. Communicable, maternal, neonatal, and nutritional disorders are shown in red, non-communicable causes in blue, and injuries in green. For the time period 1990 to 2006 and for 2006 to 2016, three measures of change are shown: median percent change in the number of YLDs, median percent change in the all-age YLD rate, and median percent change in the age-standardised YLD rate. Median values across the 1,000 draws from the uncertainty distribution are shown. Both sexes combined. YLDs=years lived with disability. COPD=chronic obstructive pulmonary disease. STDs=sexually transmitted diseases.

Top 30 Level 3 causes of YLDs for 1990, 2006, and 2016, Indonesia, both sexes

Causes are connected by arrows between time periods. Communicable, maternal, neonatal, and nutritional disorders are shown in red, non-communicable causes in blue, and injuries in green. For the time period 1990 to 2016, three measures of change are shown: percent change in the number of YLDs, percent change in the all-age YLD rate, and percent change in the age-standardised YLD rate. Numbers in bold highlight statistically significant changes.

| Leading causes 1990 | | Mean % change number of YLDs 1990-2006 | Mean % change all-age YLD rate 1990-2006 | Mean % change age- standardised YLD rate 1990-2006 | | | Mean % change number of YLDs 2006-2016 | Mean % change all-age YLD rate 2006-2016 | Mean % change age- standardised YLD rate 2006-2016 |
|---|---------------------------------|--|--|--|------------|---------------------------------|--|--|--|
| 1 Low back & neck pain | 1 Low back & neck pain | 46.3% | 14.0% | -1.4% | | 1 Low back & neck pain | 22.1% | 9.2% | -1.7% |
| 2 Skin diseases | 2 Sense organ diseases | 40.1% | 9.2% | -3.2% | | 2 Sense organ diseases | 19.8% | 7.2% | -3.6% |
| 3 Sense organ diseases | 3 Skin diseases | 24.4% | -3.0% | 1.7% | | 3 Skin diseases | 11.5% | -0.3% | 2.4% |
| 4 Migraine | 4 Migraine | 38.5% | 7.9% | -0.5% | | 4 Migraine | 15.3% | 3.1% | -0.8% |
| 5 Iron-deficiency anaemia | 5 Iron-deficiency anaemia | 17.5% | -8.5% | -6.8% | | 5 Iron-deficiency anaemia | 5.7% | -5.4% | -3.8% |
| 6 Depressive disorders | 6 Depressive disorders | 37.4% | 7.1% | -2.3% | | 6 Diabetes | 56.2% | 39.7% | 20.9% |
| 7 Anxiety disorders | 7 Other musculoskeletal disorde | rs 45.1% | 13.1% | -0.3% | | 7 Depressive disorders | 19.8% | 7.1% | -0.1% |
| 8 Other musculoskeletal disorders | 8 Anxiety disorders | 35.5% | 5.6% | 0.3% | / | 8 Other musculoskeletal disorde | s 19.8% | 7.2% | -1.5% |
| 9 Asthma | 9 Diabetes | 65.7% | 29.1% | 9.9% | | 9 Anxiety disorders | 16.1% | 3.9% | 0.0% |
| 10 Diabetes | 10 Asthma | 24.4% | -3.1% | -0.8% | < <i>/</i> | 10 COPD | 38.6% | 23.9% | 6.9% |
| 11 Diarrhoeal diseases | 11 Oral disorders | 45.3% | 13.2% | 0.1% | | 11 Oral disorders | 23.5% | 10.4% | -0.2% |
| 12 Oral disorders | 12 COPD | 72.0% | 34.1% | 13.8% | | 12 Asthma | 17.5% | 5.1% | 3.2% |
| 13 COPD | 13 Schizophrenia | 51.4% | 18.0% | 2.3% | | 13 Schizophrenia | 20.7% | 8.0% | 1.6% |
| 14 Tuberculosis | 14 Diarrhoeal diseases | -10.9% | -30.5% | -28.5% | | 14 Osteoarthritis | 39.3% | 24.6% | 4.3% |
| 15 Intestinal nematodes | 15 Epilepsy | 29.6% | 1.0% | 3.9% | | 15 Stroke | 40.4% | 25.6% | 8.5% |
| 16 Schizophrenia | 16 Osteoarthritis | 64.0% | 27.8% | 5.5% | | 16 Epilepsy | 16.4% | 4.1% | 4.9% |
| 17 Epilepsy | 17 Stroke | 64.6% | 28.3% | 9.5% | | 17 Diarrhoeal diseases | 3.9% | -7.1% | -5.9% |
| 18 Autistic spectrum disorders | 18 Other mental & substance us | e 46.4% | 14.1% | 0.2% | | 18 Other mental & substance us | e 18.9% | 6.4% | -0.1% |
| 19 Lymphatic filariasis | 19 Autistic spectrum disorders | 26.8% | -1.2% | 0.4% | | 19 Autistic spectrum disorders | 11.0% | -0.8% | 0.4% |
| 20 Conduct disorder | 20 Lymphatic filariasis | 19.9% | -6.5% | -16.1% | | 20 Drug use disorders | 16.8% | 4.4% | 6.1% |
| 21 Other mental & substance use | 21 Drug use disorders | 40.6% | 9.6% | 3.8% | \ | 21 Gynaecological diseases | 22.7% | 9.7% | 3.3% |
| 22 Osteoarthritis | 22 Neonatal preterm birth compl | icati 3:9s8% | 8.9% | 12.9% | | 22 Falls | 38.7% | 24.1% | 11.9% |
| 23 Drug use disorders | 23 Gynaecological diseases | 40.2% | 9.2% | -5.9% | 1 | 23 Bipolar disorder | 16.2% | 3.9% | -0.1% |
| 24 Neonatal preterm birth complications | 24 Bipolar disorder | 38.5% | 7.9% | 0.1% | | 24 Neonatal preterm birth compl | icatio9n.\$2% | -2.4% | 0.7% |
| 25 Gynaecological diseases | 25 Conduct disorder | 7.2% | -16.5% | 0.3% | - V | 25 Road injuries | 65.4% | 47.9% | 32.4% |
| 26 Congenital defects | 26 Tuberculosis | -16.1% | -34.6% | -37.0% | A-/ | 26 Ischaemic heart disease | 33.2% | 19.2% | 2.1% |
| 27 Bipolar disorder | 27 Upper respiratory infections | 30.9% | 2.0% | 3.9% | | 27 Conduct disorder | 4.1% | -6.9% | 0.4% |
| 28 Stroke | 28 Congenital defects | 21.8% | -5.1% | -2.9% | | 28 Upper respiratory infections | 9.0% | -2.5% | 0.1% |
| 29 Upper respiratory infections | 29 Falls | 44.7% | 12.7% | 1.4% | 1 | 29 Congenital defects | 7.0% | -4.3% | -2.6% |
| 30 Falls | 30 Ischaemic heart disease | 70.4% | 32.8% | 10.8% | // ! | 30 Tuberculosis | 2.5% | -8.3% | -16.4% |
| 35 Ischaemic heart disease | 33 Road injuries | | | | | 38 Lymphatic filariasis | | | |

Legend:

Communicable, maternal, neonatal, and nutritional Non-communicable Injuries

-----47 Intestinal nematodes

37 Road injuries

46 Intestinal nematodes

SI Figure 6. Leading 30 Level 3 risk factors for YLLs in Indonesia for 1990, 2006, and 2016, with percent change in number of YLLs, and all-age and age-standardised YLL rates

Risks are ordered by total YLLs and are connected by arrows between time periods. Environmental and occupational risks are shown in blue, metabolic risks are shown in yellow, and behavioural risks are shown in purple. For the time period 1990 to 2006 and for 2006 to 2016, three measures of change are shown: median percent change in the number of YLLs, median percent change in the all-age YLL rate, and median percent change in the age-standardised YLL rate. Median values across the 1,000 draws from the uncertainty distribution are shown. Both sexes combined. YLLs=years of life lost. Low PUFA=low polyunsaturated fatty acids.

| Leading causes 1990 | Leading causes 2006 | Mean % change number of YLLs 1990-2006 | Mean % change all-age YLL rate 1990-2006 | Mean % change age- standardised YLL rate 1990-2006 | | Leading causes 2016 | Mean % change number of YLLs 2006-2016 | Mean % change all-age YLL rate 2006-2016 | Mean % change age- standardised YLL rate 2006-2016 |
|--------------------------------------|----------------------------------|--|--|--|--------|----------------------------------|--|--|--|
| 1 Child growth failure | 1 High blood pressure | 62.4% | 26.5% | 5.6% | | 1 High blood pressure | 19.6% | 7.0% | -8.8% |
| 2 Low birth weight & short gestation | 2 Low birth weight & short gest. | -28.4% | -44.2% | -35.4% | k, , | 2 High fasting plasma glucose | 42.4% | 27.3% | 8.7% |
| 3 Unsafe sanitation | 3 Smoking | 48.8% | 15.9% | -3.8% | | 3 Smoking | 18.3% | 5.8% | -9.1% |
| 4 Unsafe water | 4 Child growth failure | -65.0% | -72.7% | -69.4% | | 4 High body-mass index | 63.7% | 46.4% | 25.4% |
| 5 Household air pollution | 5 High fasting plasma glucose | 72.3% | 34.3% | 14.9% | K X | 5 Low birth weight & short gest. | -38.7% | -45.2% | -31.0% |
| 6 High blood pressure | 6 Household air pollution | -32.5% | -47.4% | -42.2% | | 6 Low whole grains | 23.1% | 10.1% | -5.2% |
| 7 Smoking | 7 Low whole grains | 60.8% | 25.3% | 5.1% | | 7 High total cholesterol | 12.4% | 0.5% | -14.1% |
| 8 High fasting plasma glucose | 8 High total cholesterol | 57.2% | 22.5% | 2.7% | XX _ | 8 Low fruit | 8.9% | -2.6% | -16.4% |
| 9 Handwashing | 9 High body-mass index | 170.9% | 111.1% | 74.1% | | 9 Low nuts and seeds | 13.2% | 1.3% | -13.1% |
| 10 Suboptimal breastfeeding | 10 Low fruit | 42.3% | 10.9% | -7.7% | | 10 Ambient particulate matter | 0.9% | -9.7% | -16.4% |
| 11 Ambient particulate matter | 11 Ambient particulate matter | 4.2% | -18.8% | -15.1% | | 11 Low vegetables | 7.7% | -3.7% | -16.8% |
| 12 Low whole grains | 12 Low vegetables | 47.8% | 15.2% | -3.2% | | 12 Impaired kidney function | 19.3% | 6.7% | -7.4% |
| 13 High total cholesterol | 13 Low nuts and seeds | 59.9% | 24.6% | 4.7% | | 13 Household air pollution | -47.5% | -53.1% | -55.4% |
| 14 Secondhand smoke | 14 Unsafe water | -66.0% | -73.5% | -69.8% | | 14 Child growth failure | -61.8% | -65.9% | -58.8% |
| 15 Low fruit | 15 Impaired kidney function | 56.7% | 22.1% | 7.0% | | 15 Occupational injury | -0.6% | -11.1% | -13.0% |
| 16 Low vegetables | 16 Occupational injury | 21.0% | -5.7% | -14.4% | | 16 Low omega-3 | 6.3% | -5.0% | -18.4% |
| 17 Occupational injury | 17 Low omega-3 | 53.4% | 19.6% | 0.5% | | 17 Secondhand smoke | -16.3% | -25.1% | -26.1% |
| 18 Low nuts and seeds | 18 Unsafe sanitation | -74.9% | -80.4% | -77.7% | | 18 Low fibre | 3.2% | -7.7% | -20.3% |
| 19 Impaired kidney function | 19 Secondhand smoke | -26.8% | -43.0% | -32.7% | ` | 19 Unsafe water | -48.2% | -53.7% | -46.5% |
| 20 High body-mass index | 20 Low fibre | 50.4% | 17.2% | -1.9% | | 20 Low physical activity | 17.6% | 5.2% | -9.3% |
| 21 Low omega-3 | 21 Low physical activity | 61.2% | 25.6% | 4.5% | | 21 Low PUFA | 11.9% | 0.1% | -12.9% |
| 22 Vitamin A deficiency | 22 Handwashing | -65.9% | -73.5% | -70.1% | | 22 Alcohol use | 11.7% | -0.1% | -13.3% |
| 23 Low fibre | 23 Suboptimal breastfeeding | -65.7% | -73.3% | -69.5% | | 23 Low legumes | 19.2% | 6.6% | -8.2% |
| 24 Low physical activity | 24 Alcohol use | 47.7% | 15.1% | -2.0% | | 24 Unsafe sex | 46.1% | 30.6% | 11.1% |
| 25 Alcohol use | 25 Low PUFA | 47.8% | 15.2% | -2.9% | | 25 Occupational carcinogens | 35.9% | 21.5% | 2.0% |
| 26 Low PUFA | 26 Low legumes | 158.8% | 101.7% | 66.2% | | 26 High sodium | -5.0% | -15.0% | -26.6% |
| 27 High sodium | 27 High sodium | 49.1% | 16.2% | -3.1% | | 27 Unsafe sanitation | -62.1% | -66.1% | -60.9% |
| 28 Zinc deficiency | 28 Occupational carcinogens | 83.6% | 43.1% | 21.2% | | 28 Handwashing | -49.0% | -54.4% | -47.0% |
| 29 Occupational carcinogens | 29 Unsafe sex | 103.2% | 58.4% | 24.0% | Y \(\) | 29 Drug use | 40.0% | 25.2% | 13.0% |
| 30 Low legumes | 30 Lead | 68.4% | 31.2% | 15.6% | · ' | 30 Suboptimal breastfeeding | -64.8% | -68.5% | -61.2% |
| 31 Unsafe sex | 31 Drug use | | | | | 31 Lead | | | |
| 32 Lead | 33 Vitamin A deficiency | | | | | -35 Vitamin A deficiency | | | |
| 34 Drug use | 36 Zinc deficiency | | | | | -40 Zinc deficiency | | Legend: | |
| | | | | | | | | Environmenta | al/occupational risks |

Metabolic risks Behavorial risks SI Figure 7. Ratio of observed to expected age-standardised YLLs, Indonesia and comparator countries, 1990 and 2016, with uncertainty intervals

| | | χ, | ear disease | Neonatal disorders Loner respiratory intect. | | | diseases | , e | ę ⁶ | | |
|-------------|--------|--------------------|--------------------|--|--------------------|--------------------|---------------------|--------------------|--------------------|--------------------|--------------------|
| | _ | lechemic, | Neoratal | Conetress | Sticke | Diar Moed | diese Tuberculoë | e Roadiniur | CORD | Diabete s | Cirhosis |
| Indonesia | 1990 - | 0.9 [0.8 – 1] | 1.2 [1.1 – 1.5] | 1.1 [1 – 1.3] | 0.8 [0.8 – 0.9] | 4 [2.7 – 5.5] | 5.6 [5 – 6.2] | 0.8 [0.7 – 0.9] | 0.6 [0.4 – 0.7] | 0.8 [0.7 – 0.9] | 1.1 [1 – 1.3] |
| Indonesia | 2016 - | 0.9 [0.8 – 0.9] | 1.3 [1.1 – 1.5] | 0.8 [0.7 – 0.9] | 1.3 [1.2 – 1.4] | 5.2 [3.5 – 7] | 9.5 [8.9 – 10.1] | 0.7 [0.6 – 0.8] | 0.8 [0.6 – 0.9] | 2.1 [2 – 2.2] | 1.3 [1.2 – 1.4] |
| Malaysia | 1990 - | 1 [1 – 1.1] | 0.4 [0.4 – 0.5] | 0.7 [0.6 – 0.9] | 1 [0.9 – 1.1] | 0.3 [0.3 – 0.5] | 1.3 [1.1 – 1.4] | 0.9 [0.8 – 1] | 0.4 [0.3 – 0.5] | 0.7 [0.6 – 0.7] | 0.6 [0.5 – 0.7] |
| Malaysia | 2016 - | 1 [1 – 1.1] | 0.4 [0.3 – 0.6] | 2.6 [1.6 – 3.1] | 0.9 [0.9 – 1] | 1.6 [1 – 2.2] | 3.1 [2.7 – 3.5] | 1.1 [1 – 1.2] | 0.8 [0.7 – 0.9] | 1.5 [1.3 – 1.6] | 0.7 [0.6 – 0.8] |
| Philippines | 1990 - | 0.9 [0.8 – 0.9] | 1 [0.9 – 1.1] | 2 [1.8 – 2.1] | 0.7 [0.7 – 0.8] | 1 [0.9 – 1.1] | 4.3 [4 – 4.6] | 0.3 [0.3 – 0.4] | 0.5 [0.5 – 0.6] | 0.4 [0.4 – 0.4] | 0.5 [0.4 – 0.5] |
| Philippines | 2016 - | 1 [0.9 – 1.1] | 0.9 [0.8 – 1.1] | 1.9 [1.7 – 2.2] | 1.1 [1 – 1.3] | 1.5 [1.1 – 1.9] | 5.7 [4.9 – 6.6] | 0.4 [0.3 – 0.5] | 0.9 [0.7 – 1] | 1.4 [1.2 – 1.6] | 0.8 [0.7 – 1] |
| Thailand | 1990 - | 0.4 [0.4 – 0.5] | 0.7 [0.5 – 0.9] | 0.7 [0.5 – 0.9] | 0.7 [0.6 – 0.8] | 0.5 [0.3 – 0.7] | 2.7 [2.2 – 3] | 1.4 [1.3 – 1.6] | 0.9 [0.8 – 1] | 1.2 [1.1 – 1.3] | 0.9 [0.8 – 1] |
| Thailand | 2016 - | 0.3 [0.3 – 0.4] | 0.4 [0.3 – 0.6] | 1.3 [0.8 – 1.5] | 0.6 [0.5 – 0.6] | 1.6 [1 – 2.5] | 2.1 [1.8 – 2.5] | 1.3 [1.1 – 1.5] | 0.7 [0.6 – 0.8] | 1.1 [1 – 1.3] | 1 [0.8 – 1.1] |
| Vietnam | 1990 - | 0.5 [0.4 – 0.6] | 0.6 [0.5 – 0.8] | 0.6 [0.5 – 0.7] | 1.1 [1 – 1.3] | 0.3 [0.2 – 0.5] | 1.9 [1.6 – 2.3] | 0.9 [0.8 – 1.1] | 0.5 [0.3 – 0.6] | 0.7 [0.6 – 0.8] | 0.7 [0.6 – 1] |
| Vietnam | 2016 - | 0.4 [0.4 – 0.5] | 0.4 [0.3 – 0.5] | 0.5 [0.4 – 0.6] | 1 [0.9 – 1.2] | 0.2 [0.1 – 0.3] | 2.3 [1.9 – 2.8] | 0.9 [0.7 – 1.1] | 0.6 [0.5 – 0.7] | 0.9 [0.8 – 1] | 1 [0.8 – 1.3] |
| Brazil | 1990 - | 0.9 [0.8 – 0.9] | 1.1 [1 – 1.2] | 0.9 [0.8 – 1] | 0.9 [0.9 – 1] | 2.1 [1.8 – 2.3] | 0.5 [0.5 – 0.5] | 1.1 [1 – 1.1] | 0.9 [0.9 – 0.9] | 0.7 [0.7 – 0.8] | 1 [0.9 – 1] |
| Brazil | 2016 - | 0.5 [0.5 – 0.5] | 1.1 [1 – 1.2] | 1.1 [1 – 1.2] | 0.6 [0.6 – 0.6] | 1.3 [1.2 – 1.5] | 0.9 [0.9 – 1] | 1.1 [1 – 1.2] | 0.8 [0.8 – 0.9] | 1.3 [1.2 – 1.3] | 1 [0.9 – 1] |
| Turkey | 1990 - | 1 [0.9 – 1.1] | 1.5 [1.1 – 2.1] | 1.5 [1.1 – 2] | 0.4 [0.3 – 0.4] | 2 [1.3 – 2.9] | 1.1 [0.7 – 1.4] | 0.7 [0.6 – 0.8] | 0.7 [0.6 – 0.8] | 1 [0.9 – 1.1] | 0.4 [0.4 – 0.5] |
| Turkey | 2016 - | 0.6 [0.5 – 0.7] | 1.5 [1 – 2.1] | 0.4 [0.3 – 0.6] | 0.4 [0.4 – 0.5] | 0.8 [0.5 – 1.2] | 0.6 [0.5 – 0.7] | 0.6 [0.5 – 0.7] | 0.9 [0.7 – 1] | 1.3 [1.1 – 1.6] | 0.3 [0.3 – 0.4] |
| India | 1990 - | 0.9 [0.9 – 1] | 1.3 [1.2 – 1.4] | 0.9 [0.8 – 1] | 0.7 [0.6 – 0.7] | 1.5 [1.2 – 2] | 1.9 [1.7 – 2.1] | 0.6 [0.6 – 0.7] | 2.2 [1.8 – 2.7] | 0.5 [0.5 – 0.6] | 0.7 [0.7 – 0.9] |
| India | 2016 - | 1 [0.9 – 1] | 1.3 [1.2 – 1.4] | 1.1 [1 – 1.2] | 0.6 [0.6 – 0.7] | 4.1 [3 – 6.1] | 3.5 [3.3 – 3.7] | 0.7 [0.6 – 0.7] | 1.8 [1.6 – 2] | 0.8 [0.8 – 0.9] | 0.9 [0.8 – 1] |
| | | | • | * | * | * | * | * | • | 4 | |

[0.187,0.446] (0.612,0.738] (0.876,0.959] (1.08,1.3] (1.95,9.46] (0.446,0.612] (0.738,0.876] (0.959,1.08] (1.3,1.95]